Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC

For decades, the standard of care for limited-stage small cell lung cancer (LS-SCLC) has remained concurrent chemoradiation, with a 5-year survival rate hovering around 30%. While immunotherapy has transformed the treatment landscape for extensive-stage disease, its role in earlier, curable stages is still a critical clinical question.

Now, data from the Phase 3 NRG Oncology/Alliance LU005 trial, published in the Journal of Clinical Oncology, provide important insights into the timing and efficacy of immune checkpoint inhibition in this setting.

Here’s a quick overview of the findings.

Testing Concurrent Immunotherapy
The open-label, international trial enrolled 544 patients with LS-SCLC (stage Tx-IV, N0-3, M0) and an ECOG performance status of 0-2. Following one cycle of platinum/etoposide chemotherapy, patients were randomized to receive either standard concurrent chemoradiation (CRT) alone or CRT plus concurrent and adjuvant atezolizumab (1,200 mg every 3 weeks for up to 17 cycles). Radiation was delivered as either 66 Gy once daily or 45 Gy twice daily.

Survival Outcomes and Key Findings
The addition of atezolizumab to CRT did not yield a survival benefit. With a median follow-up of 23.8 months, the results showed:

• Median overall survival (OS) was 36.1 months for the CRT-alone arm compared with 31.1 months for the CRT plus atezolizumab arm (HR 1.03, 95% CI 0.80-1.32).
• Median progression-free survival (PFS) was similar between groups: 11.4 months with CRT alone versus 12.1 months with the addition of atezolizumab (HR 0.98, 95% CI 0.79-1.22).
• Distant metastasis-free survival (DMFS) also showed no significant difference, at 13.0 months for CRT alone and 16.8 months for the combination arm (HR 0.96, 95% CI 0.76-1.21).
• Objective response rates were nearly identical, at 59.6% and 60.2%, respectively.

The safety profile of concurrent atezolizumab was consistent with expectations. While grade 3-4 immune-related adverse events were higher in the atezolizumab arm (17.8% vs 6.6%), there were no unexpected safety signals or excess rates of radiation pneumonitis or esophagitis that would account for the lack of survival benefit.

Radiation Fractionation and Prophylactic Cranial Irradiation
In an exploratory analysis, the trial provided compelling data supporting the use of twice-daily radiation. Regardless of atezolizumab receipt, 45 Gy twice daily was associated with longer OS compared with 66 Gy once daily (HR 1.51 in the CRT-alone group). Additionally, patients who received prophylactic cranial irradiation (PCI) demonstrated improved OS in the CRT-alone arm (HR 0.68), with a similar trend observed in the combination arm.

Understanding the Timing of Immunotherapy
The failure of concurrent atezolizumab to improve outcomes in LU005 contrasts sharply with the recent success of the ADRIATIC trial, which demonstrated a significant survival benefit with consolidative durvalumab given after the completion of CRT. This divergence suggests that the timing of immunotherapy is critically important in LS-SCLC. The authors hypothesize that the bulky, central location of LS-SCLC tumors requires radiation fields that may inadvertently deplete the lymphocytes necessary for an effective adaptive immune response when immunotherapy is given concurrently.

Clinical Implications
For clinicians managing LS-SCLC, these findings reinforce concurrent chemoradiation alone as the standard backbone, while highlighting the importance of sequencing when incorporating immunotherapy. Notably, the CRT-alone arm in this trial established a new benchmark for survival in LS-SCLC at 36.1 months. Furthermore, the exploratory data strongly support the American Society for Radiation Oncology (ASTRO) guidelines recommending 45 Gy twice daily as the preferred radiation schedule, a regimen that remains underutilized in practice.

Reference:

Higgins KA, Hu C, Ross HJ, et al. Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. J Clin Oncol. 2026;44(8):630-640. doi:10.1200/JCO-25-01569